Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1996 Dec;87(12):1280–1287. doi: 10.1111/j.1349-7006.1996.tb03144.x

No Alteration in DNA Topoisomerase I Gene Related to CPT‐11 Resistance in Human Lung Cancer

Nobuyuki Ohashi 1, Yasuhiro Fujiwara 1,2,✉, Naoki Yamaoka 1, Osamu Katoh 3, Yukio Satow 3, Michio Yamakido 1
PMCID: PMC5921020  PMID: 9045964

Abstract

Mutations and reduced expression of DNA topoisomerase I (topo I) gene have been shown to be important in the acquisition of resistance to camptothecin and its analogues in vitro, but their significance has not been verified in vivo. We investigated possible topo I gene mutations and topo I mRNA expression levels in 127 samples obtained from 56 patients with lung tumors, including patients who had developed clinical resistance to topo I inhibitors. No mutations were detected in any of the samples examined and expression levels did not differ significantly between clinically resistant cases and others. However, the topo I mRNA expression level was significantly higher in small cell lung carcinomas than in non‐small cell lung carcinomas (P<0.05). These results suggest that topo I mRNA levels may affect CPT‐11 sensitivity in human lung cancer. However, topo I gene mutations and reduced topo I mRNA expression may not be the main mechanism of clinically acquired resistance to camptothecin analogues in vivo.

Keywords: Topoisomerase I, Point mutation, mRNA expression, CPT‐11, Lung cancer

Full Text

The Full Text of this article is available as a PDF (535.9 KB).

REFERENCES

  • 1. ) Potmesil , M.Camptothecins: from bench research to hospital wards . Cancer Res. , 54 , 1431 – 1439 ( 1994. ). [PubMed] [Google Scholar]
  • 2. ) Slichenmyer , W. J. , Rowinsky , E. K. , Donehower , R. C. and Kaufmann , S. H.The current status of camptothecin analogues as antitumor agents . J. Natl. Cancer Inst. , 85 , 271 – 291 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Giovanella , B. C. , Stehlin , J. S. , Wall , M. E. , Wani , M. C. , Nicholas , A. W. , Liu , L. F. , Silber , R. and Potmesil , M.DNA topoisomerase I‐targeted chemotherapy of human colon cancer in xenografts . Science , 246 , 1046 – 1048 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Husaine , I. , Mohler , J. L. , Seigler , H. F. and Besterman , J. M.Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor‐type specificity and implications for cancer chemotherapy . Cancer Res. , 54 , 539 – 546 ( 1994. ). [PubMed] [Google Scholar]
  • 5. ) Kanzawa , F. , Sugimoto , Y. , Minato , K. , Kasahara , K. , Bungo , M. , Nakagawa , K. , Fujiwara , Y. , Liu , L. F. and Saijo , N.Establishment of a camptothecin analogue (CPT‐11)‐resistant cell line of human non‐small cell lung cancer: characterization and mechanism of resistance . Cancer Res. , 50 , 5919 – 5924 ( 1990. ). [PubMed] [Google Scholar]
  • 6. ) Andoh , T. , Ishii , K. , Suzuki , Y. , Ikegami , Y. , Kusunoki , Y. , Takemoto , Y. and Okada , K.Characterization of a mammalian mutant with a camptothecin‐resistant DNA topoisomerase I . Proc. Natl. Acad. Sci. USA , 84 , 5565 – 5569 ( 1987. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. ) Kapoor , R. , Slade , L. , Fujimori , A. , Pommier , Y. and Harker , W. G.Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin . Oncol. Res. , 7 , 87 – 100 ( 1995. ). [PubMed] [Google Scholar]
  • 8. ) Blin , N. and Stafford , D. M.A general method for isolation of high‐molecular‐weight DNA from eukaryotes . Nucleic Acids Res. , 3 , 2303 – 2308 ( 1976. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. ) Chomczynski , P. and Sacchi , N.Single‐step method of RNA isolation by acid guanidinium thiocyanate‐phenol‐ chloroform extraction . Anal. Biochem. , 162 , 156 – 159 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Kawasaki , E. S. , Clark , S. S. , Coyne , M. Y. , Smith , S. D. , Champlin , R. , Witte , O. N. and McCormick , F. P.Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia‐specific mRNA sequences amplified in vitro . Proc. Natl. Acad. Sci. USA , 85 , 5698 – 5702 ( 1988. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. ) Mitsuhashi , M. , Cooper , A. , Ogura , M. , Shinagawa , T. , Yano , K. and Hosokawa , T.Oligonucleotide probe design ‐ a new approach . Nature , 367 , 759 – 761 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Kunze , N. , Yang , G. , Dolberg , M. , Sundarp , R. , Knippers , R. and Richter , A.Structure of the human type I DNA topoisomerase gene . J. Biol. Chem. , 266 , 9610 – 9616 ( 1991. ). [PubMed] [Google Scholar]
  • 13. ) Fujimori , A. , Harker , W. G. , Kohlhagen , G. , Hoki , Y. and Pommier , Y.Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin . Cancer Res. , 55 , 1339 – 1346 ( 1995. ). [PubMed] [Google Scholar]
  • 14. ) Rubin , E. , Pantazis , P. , Bharti , A. , Toppmeyer , D. , Giovanella , B. and Kufe , D.Identification of a mutant topoisomerase I with intact catalytic activity and resistance to 9‐nitrocamptothecin . J. Biol. Chem. , 269 , 2433 – 2439 ( 1994. ). [PubMed] [Google Scholar]
  • 15. ) Benedetti , P. , Fiorani , P. , Capuani , L. and Wang , J. C.Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine . Cancer Res. , 53 , 4343 – 4348 ( 1993. ). [PubMed] [Google Scholar]
  • 16. ) Tamura , H. , Kohchi , C. , Yamada , R. , Ikeda , T. , Koiwai , O. , Patterson , E. , Keene , J. D. , Okada , K. , Kjeldsen , E. , Nishikawa , K. and Andoh , T.Molecular cloning of a cDNA of a camptothecin‐resistant human DNA topoisomerase I and identification of mutation sites . Nucleic Acids Res. , 19 , 69 – 75 ( 1991. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. ) Kubota , N. , Kanzawa , F. , Nishio , K. , Takeda , Y. , Ohmori , T. , Fujiwara , Y. , Terashima , Y. and Saijo , N.Detection of topoisomerase I gene point mutation in CPT‐11 resistant lung cancer cell line . Biochem. Biophys. Res. Commun. , 188 , 571 – 577 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) Iizuka , N. , Oka , M. , Noma , T. , Nakazawa , A. , Hirose , K. and Suzuki , T.NM23‐H1 and NM23‐H2 messenger RNA abundance in human hepatocellular carcinoma . Cancer Res. , 55 , 652 – 657 ( 1995. ). [PubMed] [Google Scholar]
  • 19. ) Andoh , T. , Yasui , Y. , Koiwai , O. and Okada , K.Molecular basis of resistance to CPT‐11, a specific inhibitor of DNA topoisomerase I . In“The Mechanism and New Approach on Drug Resistance of Cancer Cells,” ed. Miyazaki T. , Takaku F. and Sakuraba K. , pp. 95 – 101 ( 1993. ). Excepta Medica; , Amsterdam . [Google Scholar]
  • 20. ) Hayashi , K. and Yandell , D. W.How sensitive is PCR‐SSCP ? Hum. Mutat. , 2 , 338 – 346 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Niwa , K. , Misao , R. , Hanabayashi , T. , Morishita , S. , Murase , T. , Itoh , M. , Itoh , N. , Mori , H. and Tamaya , T.Semi‐quantitative analysis of DNA topoisomerase‐I mRNA level using reverse transcription‐polymerase chain reaction in cancer cell lines: its relation to cytotoxioity against camptothecin derivative . Jpn. J. Cancer Res. , 85 , 869 – 874 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. ) Sumiyoshi , H. , Fujiwara , Y. , Ohashi , N. , Egusa , Y. , Yamaoka , N. and Yamakido , M.Clinical pharmacological evaluation of CPT‐11 and cisplatin (CDDP) in patients with small cell lung cancer (SCLC) . Proc. Am. Soc. Clin. Oncol. , 14 , 457 ( abstr. 1470 ) ( 1995. ). [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES